Display options
Cite
Casswell E, Fernandez-Sanz G, Mitry D, et al. Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case Rep Ophthalmol Med. 2014;2014:403461doi: 10.1155/2014/403461.
Casswell, E., Fernandez-Sanz, G., Mitry, D., Luk, S., & Zakir, R. (2014). Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case reports in ophthalmological medicine, 2014403461. https://doi.org/10.1155/2014/403461
Casswell, Edward, et al. "Macular Hole Progression following Ocriplasmin Intravitreal Injection." Case reports in ophthalmological medicine vol. 2014 (2014): 403461. doi: https://doi.org/10.1155/2014/403461
Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R. Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case Rep Ophthalmol Med. 2014;2014:403461. doi: 10.1155/2014/403461. Epub 2014 Dec 14. PMID: 25580329; PMCID: PMC4279821.
Copy Download .nbib Format: NLM
Share it on

Case Rep Ophthalmol Med. 2014;2014:403461. doi: 10.1155/2014/403461. Epub 2014 Dec 14.

Macular Hole Progression following Ocriplasmin Intravitreal Injection.

Case reports in ophthalmological medicine

Edward Casswell, Guillermo Fernandez-Sanz, Danny Mitry, Sheila Luk, Rahila Zakir

Affiliations

  1. Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK ; Moorfields Eye Hospital, London EC1V 2PD, UK.
  2. Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.

PMID: 25580329 PMCID: PMC4279821 DOI: 10.1155/2014/403461

Abstract

Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.

References

  1. Case Rep Ophthalmol Med. 2011;2011:679751 - PubMed
  2. N Engl J Med. 2012 Aug 16;367 (7):606-15 - PubMed
  3. Eye (Lond). 2013 Jun;27(6):773-4 - PubMed
  4. Br J Ophthalmol. 2014 Mar;98 (3):356-60 - PubMed

Publication Types